Zydus gets USFDA nod for clinical trial anti-diabetes molecule
   
Quotes

Zydus gets USFDA nod for clinical trial anti-diabetes molecule

Last Updated: Wednesday, October 23, 2013, 15:10
 
 Comment 0
 
Zydus gets USFDA nod for clinical trial anti-diabetes molecule
New Delhi: Drug firm Cadila Healthcare today said the Zydus group has received approval from the US health regulator for initiating Phase I clinical trial for ZYDPLA1 - a new molecule aimed for diabetes treatment.

Zydus group has received approval to conduct phase-I clinical trials from the US Food and Drug Administration (USFDA) for its new chemical entity (NCE), ZYDPLA, a next generation, long-acting DPP-4 inhibitor to treat type 2 diabetes, the company said in a statement.

"This novel next generation new chemical entity (NCE) would offer once-a-week oral treatment option, a significant benefit to type-2 diabetic patients," Cadila Healthcare said.

Commenting on the development, Zydus group Chairman and Managing Director Pankaj Patel said: "The IND (investigative new drug) approval by the USFDA is another major regulatory milestone for us. We believe that ZYDPLA1 holds promise and would take us closer to our mission of reducing the burden of chronic diseases and addressing the unmet needs in treatment of diabetes."

In June, Cadila Healthcare, a part of the Zydus Group, had received regulatory approval to market its diabetes drug Lipaglyn in India.

Patel had said Zydus group expected at least two molecules out of 20 under its discovery research programmes to become successful by 2020.



PTI

First Published: Wednesday, October 23, 2013, 15:10


Comments


comments powered by Disqus
New Generation Scorpio
New Generation Scorpio
BRICS SUMMIT Ufa
BRICS SUMMIT Ufa
New Vento 2015
New Vento 2015
Audi all-new SUV Q3
Audi all-new SUV Q3
Indian Billionaire Daughters
Indian Billionaire Daughters

Contact Us : Privacy Policy : Legal Disclaimer
Copyright © Zee Media Corporation Ltd. All rights reserved